Vascodagama Online Journal

Esophageal Squamous Cell Carcinoma Pipeline Assets are Segmented by Stage, Product Type, Route of Administration, and Molecule Type

 Breaking News
  • No posts were found

Esophageal Squamous Cell Carcinoma Pipeline Assets are Segmented by Stage, Product Type, Route of Administration, and Molecule Type

March 13
20:41 2023
Esophageal Squamous Cell Carcinoma Pipeline Assets are Segmented by Stage, Product Type, Route of Administration, and Molecule Type

DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including Esophageal Squamous Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Esophageal Squamous Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Esophageal Squamous Cell Carcinoma Emerging drugs, the Esophageal Squamous Cell Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Esophageal Squamous Cell Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Esophageal Squamous Cell Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Esophageal Squamous Cell Carcinoma clinical trials studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

 

  • DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.

 

  • The leading Esophageal Squamous Cell Carcinoma Companies includes BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, and others. 

 

  • Promising Esophageal Squamous Cell Carcinoma Pipeline Therapies includes KN046, Tislelizumab, IBI308, paclitaxel/ irinotecan, Anlotinib, LJM716, BYL719, Cisplatin, Oxaliplatin, and others.

 

  • The Esophageal Squamous Cell Carcinoma companies and academics that are working to assess challenges and seek opportunities that could influence Esophageal Squamous Cell Carcinoma R&D. The Esophageal Squamous Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Request a sample and discover the recent breakthroughs happening in the Esophageal Squamous Cell Carcinoma Pipeline landscape @ Esophageal Squamous Cell Carcinoma Pipeline Outlook Report

 

Esophageal Squamous Cell Carcinoma Overview

Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics.

 

Recent Developmental Activities in Esophageal Squamous Cell Carcinoma Treatment Landscape

 

  • In August 2022, BeiGene announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) had accepted a supplemental biologics license application (sBLA) for tislelizumab in combination with chemotherapy as first-line treatment in patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

 

  • In July 2022, Novartis announced results from the Phase-III Rationale 306 trial showing tislelizumab plus chemotherapy significantly improved the Overall Survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic Esophageal Squamous Cell Carcinoma (ESCC), regardless of PD-L1 status. Tislelizumab plus chemotherapy demonstrated a median OS of 17.2 months (CI, 15.8-20.1 months) versus 10.6 months (CI, 9.3-12.1 months) in patients receiving chemotherapy plus placebo and reduced the risk of death by 34 per cent (hazard ratio=0.66; CI, 0.54-0.80, p<0.0001). In collaboration with BeiGene, these data were presented during a late-breaking oral session at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.

 

  • In June 2022, Innovent Biologics Inc. and Eli Lilly and Company announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) had approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

 

  • In May 2022, Bristol Myers Squibb, announced that the U.S. Food and Drug Administration (FDA) had approved both Opdivo (nivolumab) (injection for intravenous use) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status. The approvals are based on the Phase III CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) each compared to chemotherapy alone (n=324), and was the largest Phase III trial of immunotherapy in first-line ESCC.

 

  • In May 2022, Shanghai Junshi Biosciences Co., Ltd, announced that the China National Medical Products Administration (NMPA) had approved the supplemental new drug application (sNDA) for toripalimab in combination with paclitaxel and cisplatin in the first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The sNDA was accepted by the NMPA in July 2021. This is the fifth indication approved for toripalimab in China and will benefit Chinese patients with advanced ESCC.

 

  • In April 2022, BeiGene, Ltd. announced that the China National Medical Products Administration (NMPA) had granted approval to BeiGene’s anti-PD-1 antibody, tislelizumab, as a treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression or are intolerant to first-line standard chemotherapy.

 

  • In January 2022, Lyell Immunopharma, Inc., announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to initiate a Phase I clinical trial for LYL132, an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that the company is developing in collaboration with GSK. 

 

For further information, refer to the detailed Esophageal Squamous Cell Carcinoma Drugs Launch, Esophageal Squamous Cell Carcinoma Developmental Activities, and Esophageal Squamous Cell Carcinoma News, click here for Esophageal Squamous Cell Carcinoma Ongoing Clinical Trial Analysis

 

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

 

  • Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.

 

  • Serplulimab: Shanghai Henlius Biotech

Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).

 

Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Esophageal Squamous Cell Carcinoma. The companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

 

Find out more about the Esophageal Squamous Cell Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Esophageal Squamous Cell Carcinoma Emerging Drugs @ Esophageal Squamous Cell Carcinoma Treatment Landscape

 

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, and others.

 

  • Esophageal Squamous Cell Carcinoma Pipeline Therapies- KN046, Tislelizumab, IBI308, paclitaxel/ irinotecan, Anlotinib, LJM716, BYL719, Cisplatin, Oxaliplatin, and others

 

  • Esophageal Squamous Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of administration

 

Dive deep into rich insights for drugs for Esophageal Squamous Cell Carcinoma Pipeline Companies and Therapies, click here @ Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Esophageal Squamous Cell Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Tislelizumab: BeiGene
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RAPA-201: Rapa Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. SGN-B6A: Seagen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Esophageal Squamous Cell Carcinoma Key Companies
  21. Esophageal Squamous Cell Carcinoma Key Products
  22. Esophageal Squamous Cell Carcinoma- Unmet Needs
  23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
  24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
  25. Esophageal Squamous Cell Carcinoma Analyst Views
  26. Esophageal Squamous Cell Carcinoma Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Esophageal Squamous Cell Carcinoma Mergers and acquisitions, Esophageal Squamous Cell Carcinoma Licensing Activities @ Esophageal Squamous Cell Carcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories